Literature DB >> 17828496

Knockdown of survivin expression by siRNA induces apoptosis of hepatocellular carcinoma cells.

Liang Wu1, Ying Wang, Deying Tian.   

Abstract

Survivin, a newly identified member of IAP family, is a powerful apoptosis-inhibiting factor. It is expressed in embryonic tissues as well as in the majority of human cancers, but not in most normal adult tissues. The cancer-specific expression of survivin makes it a potential target for cancer treatment. A survivin-specific small inhibitory RNA (siRNA) was introduced into hepatocellular carcinoma cells to investigate its effect on cancer cell apoptosis, growth and sensitivity to chemotherapeutic drugs. It was found that expressions of survivin protein and proliferation index (PI) in siRNA groups were significantly decreased, the apoptosis index (AI) of siRNA groups was significantly higher than those of others groups, and the growth inhibition rate (GIR) of chemotherapeutic drugs in siRNA groups were significantly higher than those of other groups. Our study suggests that the expression of survivin may be significantly decreased in hepG2 cell after siRNA transfection. siRNA targeting survivin could induce cell apoptosis, inhibit cell proliferation and sensitize hepatocarcinoma cells to chemotherapy. Our findings provide preliminary evidence for the therapeutic use of survivin-targeted RNA interference for human tumors that express high levels of this molecule.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17828496     DOI: 10.1007/s11596-007-0413-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  12 in total

1.  Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways.

Authors:  S L Shankar; S Mani; K N O'Guin; E R Kandimalla; S Agrawal; B Shafit-Zagardo
Journal:  J Neurochem       Date:  2001-10       Impact factor: 5.372

Review 2.  RNA interference in biology and disease.

Authors:  Carol A Sledz; Bryan R G Williams
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

Review 3.  RNA interference as a gene-specific approach for molecular medicine.

Authors:  A Grünweller; R K Hartmann
Journal:  Curr Med Chem       Date:  2005       Impact factor: 4.530

Review 4.  Survivin as a target for new anticancer interventions.

Authors:  Nadia Zaffaroni; Marzia Pennati; Maria Grazia Daidone
Journal:  J Cell Mol Med       Date:  2005 Apr-Jun       Impact factor: 5.310

Review 5.  Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice.

Authors:  Aaron D Schimmer
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

6.  Transgenic expression of survivin in keratinocytes counteracts UVB-induced apoptosis and cooperates with loss of p53.

Authors:  D Grossman; P J Kim; O P Blanc-Brude; D E Brash; S Tognin; P C Marchisio; D C Altieri
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 7.  An IAP in action: the multiple roles of survivin in differentiation, immunity and malignancy.

Authors:  Uwe Zangemeister-Wittke; Hans-Uwe Simon
Journal:  Cell Cycle       Date:  2004-09-15       Impact factor: 4.534

Review 8.  Cancer immunotherapy targeting survivin: commentary re: V. Pisarev et al., full-length dominant-negative survivin for cancer immunotherapy. Clin. Cancer Res., 9:6523-6533, 2003.

Authors:  John C Reed; Darcy B Wilson
Journal:  Clin Cancer Res       Date:  2003-12-15       Impact factor: 12.531

Review 9.  Role of survivin and its splice variants in tumorigenesis.

Authors:  F Li
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

Review 10.  The therapeutic potential of RNA interference.

Authors:  Susan L Uprichard
Journal:  FEBS Lett       Date:  2005-08-15       Impact factor: 4.124

View more
  1 in total

1.  Altered regulation of extrinsic apoptosis pathway in HCV-infected HCC cells enhances susceptibility to mapatumumab-induced apoptosis.

Authors:  Xiaozhen Zhang; Astrid C Frank; Christine M Gille; Marybeth Daucher; Juraj Kabat; Steven Becker; Richard A Lempicki; Karoll J Cortez; Michael A Polis; G Mani Subramanian; Shyam Kottilil
Journal:  Hepatol Res       Date:  2009-09-25       Impact factor: 4.288

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.